HomeCompareMSSV vs PFE

MSSV vs PFE: Dividend Comparison 2026

MSSV yields 7692.31% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MSSV wins by $4177739098279589.00M in total portfolio value
10 years
MSSV
MSSV
● Live price
7692.31%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4177739098279589.00M
Annual income
$4,073,565,928,588,968,500,000.00
Full MSSV calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — MSSV vs PFE

📍 MSSV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMSSVPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MSSV + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MSSV pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MSSV
Annual income on $10K today (after 15% tax)
$653,846.15/yr
After 10yr DRIP, annual income (after tax)
$3,462,531,039,300,623,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, MSSV beats the other by $3,462,531,039,300,623,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MSSV + PFE for your $10,000?

MSSV: 50%PFE: 50%
100% PFE50/50100% MSSV
Portfolio after 10yr
$2088869549139794.50M
Annual income
$2,036,782,964,294,484,200,000.00/yr
Blended yield
97.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

MSSV
No analyst data
Altman Z
-34.3
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MSSV buys
0
PFE buys
0
No recent congressional trades found for MSSV or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMSSVPFE
Forward yield7692.31%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$4177739098279589.00M$49.6K
Annual income after 10y$4,073,565,928,588,968,500,000.00$26,258.71
Total dividends collected$4170772265337663.00M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MSSV vs PFE ($10,000, DRIP)

YearMSSV PortfolioMSSV Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$779,931$769,230.77$9,153$693.39+$770.8KMSSV
2$56,904,315$56,069,789.30$8,593$849.25+$56.90MMSSV
3$3,884,151,673$3,823,264,055.84$8,336$1,066.78+$3884.14MMSSV
4$248,050,254,929$243,894,212,638.74$8,437$1,384.80+$248050.25MMSSV
5$14,822,056,221,428$14,556,642,448,653.80$9,013$1,875.40+$14822056.21MMSSV
6$828,776,618,419,079$812,917,018,262,150.50$10,306$2,680.72+$828776618.41MMSSV
7$43,367,472,132,823,630$42,480,681,151,115,220.00$12,820$4,101.38+$43367472132.81MMSSV
8$2,123,871,047,251,591,000$2,077,467,852,069,469,400.00$17,673$6,826.70+$2123871047251.57MMSSV
9$97,358,102,514,598,310,000$95,085,560,494,039,100,000.00$27,543$12,591.86+$97358102514598.28MMSSV
10$4,177,739,098,279,589,000,000$4,073,565,928,588,968,500,000.00$49,560$26,258.71+$4177739098279589.00MMSSV

MSSV vs PFE: Complete Analysis 2026

MSSVStock

Meso Numismatics, Inc. engages in the numismatic business in the United States and internationally. The company sells coins, paper currency, bullion, and medals through live auctions. It also offers banknote scanner, an application to identify key characteristics of a banknote; and sells its products through an online store, mesocoins.com. In addition, the company provides CELLGENIC FLOW EXOSOMES; CELLGENIC MSC, which excretes growth factors, cytokines, and proteins for regeneration of tissue; CELLGENIC LUMA that is derived from human umbilical cord mesenchymal stem cells, including potent growth factors, peptides, coenzymes, minerals, amino acids, vitamins, and UV radiation reducing agents for skin revitalization; VITANOVAS that offers in-home treatments to patients in need of immune modulation to help fight infections, viruses, and diseases; GCELL RESTORE, a closed-system medical device to harness the natural and restorative capabilities of adipose tissue; CELLGENIC SVF, an isolation kit system that has the ingredients and consumables for the extraction of adipose-derived stem cells from fat; CELLGENIC BONE MARROW; and CELLGENIC Platelet Rich Plasma for healing and reducing inflammation. Further, it offers training services to doctors. The company was formerly known as Pure Hospitality Solutions, Inc. and changed its name to Meso Numismatics, Inc. in September 2018. Meso Numismatics, Inc. was founded in 1999 and is based in Boca Raton, Florida.

Full MSSV Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this MSSV vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MSSV vs SCHDMSSV vs JEPIMSSV vs OMSSV vs KOMSSV vs MAINMSSV vs JNJMSSV vs MRKMSSV vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.